Development of antimalarial histone deacetylase inhibitors

抗疟组蛋白脱乙酰酶抑制剂的开发

• 批准号: nhmrc : GNT1093378
• 负责人: Prof David Fairlie
• 金额: $ 55.68万
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-antimalarial-histone-deacetylase-inhibitors/1345917
• 关键词: Development; antimalarial; histone; deacetylase; inhibitors

Human histone deacetylases (HDACs) are enzymes clinically validated as targets for cancer chemotherapy. Different HDAC enzymes are important for survival of infectious organisms, such as protozoan Plasmodium parasites that cause malaria. This project will develop promising drug leads that kill the parasites without damaging human cells through preclinical studies in mice towards a future clinical trial for the treatment of malaria in humans.

人组蛋白脱乙酰酶（HDAC）是临床上被验证为癌症化疗靶点的酶。不同的HDAC酶对于感染性生物体的存活是重要的，例如引起疟疾的原生动物疟原虫寄生虫。该项目将开发有前景的药物先导物，通过小鼠临床前研究杀死寄生虫而不损害人体细胞，以用于未来治疗人类疟疾的临床试验。